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Experimental studies about Leishmania resistance to metal and antifolates have pointed out that gene ampliﬁcation is one of the
main mechanisms of drug detoxiﬁcation. Ampliﬁed genes code for adenosine triphosphate-dependent transporters (multidrug
resistance and P-glycoproteins P), enzymes involved in trypanothione pathway, particularly gamma glutamyl cysteine synthase,
and others involved in folates metabolism, such as dihydrofolate reductase and pterine reductase. The aim of this study was to
detect and quantify the ampliﬁcation of these genes in clinical strains of visceral leishmaniasis agents: Leishmania infantum, L.
donovani,a n dL. archibaldi. Relative quantiﬁcation experiments by means of real-time polymerase chain reaction showed that
multidrug resistance gene ampliﬁcation is the more frequent event. For P-glycoproteins P and dihydrofolate reductase genes, level
of ampliﬁcation was comparable to the level observed after in vitro selection of resistant clones. Gene ampliﬁcation is therefore
a common phenomenon in wild strains concurring to Leishmania genomic plasticity. This ﬁnding, which corroborates results of
experimental studies, supports a better understanding of metal resistance selection and spreading in endemic areas.
1.Introduction
Visceral leishmaniasis (VL) constitutes a public health
problem in East Africa, Asia, Mediterranean basin, and
Central and South America. It is estimated that about
500000 new cases occur each year. In East Africa and
India, VL cause large-scale and tenacious epidemics with
high case-fatality rates [1]. In numerous countries that
cannot aﬀord the cost of liposomal amphotericin B, ﬁrst line
treatment still relies on sodium stibogluconate or N-methyl
glucamine [2]. Cases refractory to antimony treatment
have been described for a long time in humans [3]a s
well as in dogs [4]. During the last decades, incidence of
resistance to antimony drugs in Leishmania spp. increased
dramatically in some VL foci [5]. The mechanisms con-
tributing to drug resistance in vivo are poorly understood.
In vitro studies of strains selected for metal resistance
showed that several independent pathways could concur to
the resistance phenotype [6]. Among them, overexpression
of energy dependent transporters seems to play a major
role in resistance to antimonials (reviewed in [7]). Genes
coding for “ATP binding cassette” (ABC) transporters [8]
and multidrug resistance (MDR) genes [9]h a v eb e e n
shown to be ampliﬁed as extrachromosomal elements in
strains selected in vitro for resistance to heavy-metals. Some
works showed that genes that concur to glutathione and
trypanothione synthesis can also be ampliﬁed in resistant
parasites [10]. Gene ampliﬁcation has been also described
in Leishmania strains selected for resistance to methotrexate
[11]. Other molecules are involved in trivalent antimony
or arsenite compounds transport like aquaglyceroporins
whose down regulation provides resistance to trivalent anti-
mony and mutation could aﬀect speciﬁcally metal transport
[12].
However, all these ﬁndings derived from studies of
strains whose resistance was induced in vitro and data
about natural conditions are lacking. The aim of the present
study was therefore to evaluate both the frequency of gene
ampliﬁcation and the ampliﬁcation level of genes involved in
drug resistance among Leishmania clinical strains.2 International Journal of Microbiology
2.MaterialsandMethods
2.1. Leishmania Strains. The study included 90 Leishmania
strains isolated from French and Sudanese VL foci.
Sixty L. infantum strains were collected in France from
16 HIV positive patients presenting with autochthonous VL.
When relapses occurred, we performed successive parasite
isolations: for each patient, the number of isolates varied
from two to seven and the duration of the survey was 10 to
1800 days (Table 1).
Twentysevenstrains(ﬁfteenL.donovani,sixL.archibaldi
and six L. infantum), were isolated from 27 Sudanese
patients. Any of these patients were infected by HIV.
Three other strains (two L. donovani and one L. infantum)
were isolated from Sudanese post-Kala-Azar dermatitidis
leishmaniasis (PKDL) patients (Table 2).
All strains were identiﬁed, typed, and cryopreserved at
the National Reference Centre for Leishmaniasis (Montpel-
lier, France).
A Leishmania infantum strain, isolated from a dog in
an area without any therapeutic pressure (MCAN/82/GR/
MON497), was used as reference (calibrator) for the relative
quantiﬁcation experiments. In vitro sensitivity assays have
conﬁrmed the sensitivity of this strain to antimonials [13].
It was grown using the same conditions as the studied
strains.
2.2.DNAExtraction. ParasitesweregrowninRPMImedium
(containing 10% foetal calf serum, gentamycin, all from
Sigma); cells were harvested by centrifugation, and washed
twice with PBS before DNA extraction. DNA was puriﬁed
from 5 106 promastigotes by means of a QiaAmp DNA
mini kit (Qiagen ref 51034) according to the manufacturer
speciﬁcations. Elution was performed with 100μLo fD N A s e
free water and the concentration was measured by spec-
trophotometry. DNA solutions were kept frozen (−40◦C)
until use.
2.3. Relative Quantiﬁcations of the Genes Under Study.
We focused on the following genes: two ATP-dependant
drug transporters, MDR 1 and P-glycoproteins P A (PGP
A); one gene involved in glutathione and trypanothione
synthesis, the G-glutamylcysteine synthetase (GSH1); two
genes involved in the folate metabolism pathways, dihydro-
folatereductase-thymidlatesynthase(DHFR-TS)andpterine
reductase (PTR1).
We measured their ampliﬁcation levels by means of real-
time PCR, relatively to invariant genes. We used two single
copy genes as reference genes: the DNA polymerase [14]a n d
the ascorbate-dependant peroxidase [15]. Primers and probe
targetting the DNA polymerase gene were chosen according
to Bretagne et al. [16]. For the ascorbate-dependant per-
oxidase and the genes under study, speciﬁc sequences were
extracted from Genbank (http://www.ncbi.nlm.nih.gov/)
and primers and TaqMan probes were designed by means of
Primer3 software (http://frodo.wi.mit.edu/primer3). Table 3
summarizes the sequences of all primers and probes used in
this study.
All assays were duplex PCR, performed in duplicate
experiments, on a Stratagene MX 4000 thermal cycler with
a multiplex QPCR ready-to-use mix (Stratagene, ref 600549-
51). Each assay was performed by using 0.1ng of sample
D N Aa st e m p l a t e .T h e r m a lp r o ﬁ l ew a s9 4 ◦Cf o r1 0m i n u t e s
for polymerase activation, 94◦C3 0s ,5 4 ◦C 30s, 45 cycles. All
the samples results were compared to those of the reference
strain by means of the delta (delta Ct) method; this method
calculate, for each sample, the level of the genes of interest
relatively to the invariants genes and then standardize the
results by means of the calibrator [17].
2.4. Statistical Analysis. Statistical analysis was computed
using the SAS Stat 9.1.3 (SAS, Cary, NC, USA) statistical
software. Whether the occurrence of gene ampliﬁcation
was associated with Leishmania species was tested for each
studied gene using the Pearson Chi-squared test.
3. Results
3.1. Thresholds. For each gene studied, we need to estimate
a threshold for ampliﬁcation. In this aim, we determined
the gene ampliﬁcation levels of the sensitive reference strain
from ten biological replicates. We considered this level as a
sensitive reference value. The threshold deﬁning signiﬁcant
gene ampliﬁcation was ﬁxed by calculating the mean value
of the 10 replicates augmented of 3 standard deviations to
avoid over estimation of gene ampliﬁcation. Table 4 presents
means, standard deviations, and thresholds for the genes
of interest; all ampliﬁcation thresholds were therefore lower
than 2, indicating that our assays were able to discriminate
at least a two fold gene ampliﬁcation relatively to the chosen
reference.
3.2. Evidence of Drug Resistance Genes Ampliﬁcation in Field
Strains. Data concerning the intensity and the frequency of
gene ampliﬁcation in the strains under study are presented
in Tables 1, 2,a n d4. Statistics took only in account results of
the initial strain isolated from the French patients.
MDR 1 gene was at least twice ampliﬁed in 30 of the 46
primitive strains, representing 65% of the cases. GSH was
ampliﬁed in onlythree Sudanese strains (meanampliﬁcation
level = 2.41). In the ﬁrst strain, GSH ampliﬁcation was
associated with PGP A, MDR 1, and PTR1 ampliﬁcation; in
the second, GSH ampliﬁcation was associated with PGP A
and MDR 1 ampliﬁcation; in the third, GSH ampliﬁcation
was associated with MDR 1 ampliﬁcation.
Five out of the 16 French patients primitive strains
showed DHFR gene ampliﬁcation; in four of these strains
MDR 1 gene was also ampliﬁed.
3.3. Stability of Gene Ampliﬁcation Level among Successive
Strains from the Same Patient. We analysed gene copy
number variations in the sequential strains from the 16
French patients. Variations of the PGP A, MDR 1, GSH,
DHFR and PTR genes ampliﬁcation with respect to the
initial level were less than or equal to 28%, 34%, 25%, 33%,International Journal of Microbiology 3
Table 1: Main characteristics of the isolates and results of relative quantiﬁcation of resistance genes for French VL patients. NA:
nonampliﬁed.
Patients Parasite identiﬁcation Site/time of isolation PGP MDR GSH DHFR PTR1
F1
L. infantum MON 24 blood j 0 1.12 3.22 0.85 0.94 0.91
L. infantum MON 24 blood j 30 0.78 2.83 0.79 0.67 0.96
L. infantum MON 24 bone marrow j130 0.94 4.17 0.75 0.48 0.96
F2 L. infantum MON 24 blood j 0 3.07 6.1 0.93 1.04 1.05
L. infantum MON 24 peau j10 3.64 4.86 0.88 0.97 0.91
F3
L. infantum MON 33 blood j 0 1.3 4.05 0.95 0.75 1.02
L. infantum MON 33 blood j 90 1.67 3.87 0.94 0.66 1.03
L. infantum MON 33 blood j 250 1.18 5.41 0.88 0.6 0.99
L. infantum MON 33 blood j 540 0.94 4.83 0.86 0.81 0.98
L. infantum MON 33 blood j 1020 1.6 4.4 0.78 0.75 0.86
L. infantum MON 33 blood j 1440 1.32 3.67 0.73 0.83 0.84
L. infantum MON 33 blood j 1830 1.01 4.82 0.73 0.73 0.93
F4 L. infantum MON 1 blood j 0 1.2 5.52 0.97 15.59 0.74
L. infantum MON 1 blood j 100 1.21 6.26 1.01 16.2 0.73
F5
L. infantum MON 1 cavum j 0 1.78 3.01 1.01 1.48 1.05
L. infantum MON 1 blood j 90 1.91 3.97 0.94 1.31 1.07
L. infantum MON 1 blood j 180 1.57 3.44 0.71 0.87 1.11
L. infantum MON 1 skin j 180 2.13 4.3 0.65 0.89 0.94
F6
L. infantum MON 1 blood j 0 1.53 12 1.25 11.5 1.11
L. infantum MON 1 blood j 450 1.19 8.72 1.28 19.1 1.17
L. infantum MON 1 blood j 810 1.29 8.4 1.64 12.8 1.12
F7 L. infantum MON 24 bone marrow j 0 1.12 3.94 0.86 0.71 0.85
L. infantum MON 24 bone marrow j 30 1.13 3.97 0.83 0.62 0.77
F8
L. infantum MON 1 blood j 0 1.02 4.06 1.05 7.39 1.11
L. infantum MON 1 bone marrow j 15 1.11 3.02 1.08 10.7 1.08
L. infantum MON 1 blood j 660 1.82 2.68 0.97 5.71 0.96
L. infantum MON 1 blood j 720 7.84 2.8 0.85 5.03 0.91
L. infantum MON 1 blood j 850 7.49 3.73 0.85 5.09 0.93
F9
L. infantum MON 24 blood j 0 1.02 5.32 1 16.05 0.66
L. infantum MON 24 blood j 10 0.88 4.61 0.8 16.8 0.67
L. infantum MON 24 blood j 110 0.96 7.88 1.02 15.1 0.69
L. infantum MON 24 blood j 390 0.94 7.4 0.67 9.98 0.64
L. infantum MON 24 blood j 1140 0.98 8.67 1.42 5.89 0.66
L. infantum MON 24 blood j 1240 0.95 6.68 1.3 11.7 0.68
F10
L. infantum MON 24 blood j 0 1.1 5.05 0.72 0.83 0.74
L. infantum MON 24 blood j 15 0.62 4.01 0.58 0.81 0.71
L. infantum MON 24 blood j 50 1.2 4.19 0.81 0.85 0.65
L. infantum MON 24 blood j 80 1.13 3.67 0.65 0.96 0.67
L. infantum MON 24 blood j 420 0.99 5.48 0.63 0.91 0.71
F11 L. infantum MON 1 bone marrow j 0 1.47 5.32 0.67 0.92 0.73
L. infantum MON 1 bone marrow j 110 1.67 4.56 0.6 0.61 0.79
F12
L. infantum MON 1 bone marrow j 0 1.65 4.04 0.83 0.85 NA
L. infantum MON 1 bone marrow j360 1.78 6.75 0.75 0.76 NA
L. infantum MON 1 blood j 810 2.58 4.22 0.66 0.67 NA
L. infantum MON 1 blood j 1800 2.07 4.58 0.85 0.67 NA
F13
L. infantum MON 24 bone marrow j 0 0.71 1.66 0.74 2.49 0.86
L. infantum MON 24 skin j 4 1.28 2.17 0.81 1.19 0.81
L. infantum MON 24 blood j 810 0.82 1.77 0.74 1.36 0.824 International Journal of Microbiology
Table 1: Continued.
Patients Parasite identiﬁcation Site/time of isolation PGP MDR GSH DHFR PTR1
F14
L. infantum MON 24 blood j 0 0.76 5.22 0.87 0.69 0.8
L. infantum MON 24 blood j 10 0.78 4.9 0.75 0.56 0.82
L. infantum MON 24 blood j 165 0.95 4.89 0.61 0.73 0.84
L. infantum MON 24 blood j 420 0.98 5.61 0.59 0.87 0.78
L. infantum MON 24 blood j 630 0.66 4.56 0.63 1 0.75
F15
L. infantum MON 24 blood j 0 1 3.42 1.31 0.61 1
L. infantum MON 24 blood j 240 0.89 3.97 0.69 0.73 0.93
L. infantum MON 24 blood j 400 0.73 4.07 0.68 0.59 0.96
L. infantum MON 24 blood j 580 1.48 5.09 0.64 0.8 0.95
F16
L. infantum MON 1 bone marrow j 0 0.86 3.68 0.82 1.53 0.91
L. infantum MON 1 skin j 710 0.82 3.05 0.52 2.05 0.92
L. infantum MON 1 blood j 1700 0.92 4.31 0.51 2.21 0.81
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Figure 1: Variations of PGP A gene ampliﬁcation among the
successive Leishmania isolates from patient F8.
and 10%, respectively, except for the increase of PGP A
ampliﬁcation level observed in one patient (F8). This case
corresponded to a patient initially treated with N methyl
glucamine and he relapsed 22 months after initial disease.
For this patient, the two last strains, collected during relapse,
presented with PGP A ampliﬁcation levels of 7.84 and 7.49
instead of an initial level of 0.45 before the ﬁrst treatment
course (Figure 1).
3.4. Gene Ampliﬁcation Frequency in Leishmania Species.
We tested the eventual association between the species
L. archibaldi, L. donovani (absent in the Mediterranean
focus), L. infantum (present in the two studied foci), and
gene ampliﬁcation. Only MDR 1 ampliﬁcation, which was
observed in 83% of the L. infantum strains, was statistically
(P = .04) associated with the species (Table 5).
4. Discussion
Several studies aimed to document gene ampliﬁcation
among Leishmania genome of strains selected under in vitro
drug pressure and its involvement in resistance mechanisms
[18].Theﬁrstapproachusedhybridisationexperimentsafter
standardization of the samples by means of a housekeep-
ing gene [8]. More recently, micro array technology was
developed; a large number of genes could be analysed into
a single experiment, improving the screening capacity. This
technology conﬁrmed the involvement of gene ampliﬁcation
inLeishmaniaresistancetoantimonyandwascomplemented
by other techniques for ﬁnest quantiﬁcation of the variable
genes [10, 19]. A better accuracy is obtained by means of
comparative real-time PCR, quantifying the number of copy
of a target gene to one or more housekeeping genes.
We analysed ampliﬁcation of ﬁve genes involved in drug
resistanceonthebasisofexperimentalstudies.Ourapproach
was reproducible enough to appreciate a two fold increase
in gene ampliﬁcation but presents some limiting aspects. A
clear correlation between clinical response to therapy and
gene ampliﬁcation was impossible to establish because most
of the French patients were treated with liposomal ampho-
tericin B and we lack precise information about response to
meglumine antimoniate administration in Sudanese cases.
Other mechanisms than gene ampliﬁcation are involved in
resistance to treatment such as over expression, the two
phenomenons being sometimes linked [20]. In this study,
promastigotes were tested after 5 to 8 in vitro passages;
we hypothesized that the studied characters were stable,
as described by others authors in vivo [21]a n din vitro
[22]. Nevertheless, we believe our results highlight some
signiﬁcant aspects of the phenomenon of drug resistance of
Leishmania that need further discussion.
Our main ﬁndings show that gene ampliﬁcation, initially
described in experimental studies about drug resistance of
laboratory mutants, can also be encountered in Leishmania
ﬁeld strains.
The most frequently ampliﬁed gene was the MDR 1
gene, which was found ampliﬁed in 65% of the strains withInternational Journal of Microbiology 5
Table 2: Main characteristics of the isolates and results of relative quantiﬁcation of resistance genes for Sudanese patients. All patients were
visceral leishmaniasis patients except S28, S29, and S30 who presented with post kala-azar dermal leishmaniasis. NA: nonampliﬁed.
Patients Parasite identiﬁcation Site of isolation PGP MDR GSH DHFR PTR1
S1 L. donovani MON 18 lymph node 0.98 1.21 0.85 1.01 1.03
S2 L. donovani MON 18 lymph node 4.47 19.4 2.93 0.93 1.49
S3 L. donovani MON 18 lymph node 1.28 2.71 0.92 0.98 0.85
S4 L. donovani MON 18 lymph node 0.78 1.21 1.04 1.03 2.03
S5 L. donovani MON 18 lymph node 0.97 6.16 1.61 1.02 1.03
S6 L. donovani MON 18 lymph node 0.8 5.49 0.62 0.75 0.86
S7 L. donovani MON 18 lymph node 0.82 NA 1.02 1.05 1.02
S8 L. donovani MON 18 lymph node NA 0.96 0.85 NA 0.91
S9 L. donovani MON 18 lymph node NA 0.78 0.95 NA 0.85
S10 L. donovani MON 18 lymph node 1.05 0.99 0.61 1.02 1.05
S11 L. donovani MON 18 lymph node 4.54 1.02 0.69 NA NA
S12 L. donovani MON 18 lymph node 1.52 1.48 NA 1.07 0.98
s1 3 L. donovani MON 18 lymph node 1.07 1.74 NA NA NA
S14 L. donovani MON 18 lymph node 1.17 2.72 1.04 0.98 2.7
S15 L. donovani MON 18 lymph node 0.94 4.68 0.95 0.95 0.86
S16 L. archibaldi MON 257 lymph node 0.87 0.98 1.04 1.02 NA
S17 L. archibaldi MON 257 lymph node 0.81 5.25 0.72 1.05 1.04
S18 L. archibaldi MON 258 lymph node 1.06 2.7 0.77 0.97 NA
S19 L. archibaldi MON 257 lymph node 0.92 1.33 0.98 0.85 0.83
S20 L. archibaldi MON 257 lymph node 1.13 4.47 0.79 1.03 NA
S21 L. archibaldi MON 257 lymph node 1.55 2.24 0.87 0.93 NA
S22 L. infantum MON 30 lymph node 7.83 3.62 1.12 0.83 0.97
S23 L. infantum MON 30 lymph node 0.99 1.74 0.77 0.92 NA
S24 L. infantum MON 30 lymph node 0.72 2.96 1.04 0.73 0.68
S25 L. infantum MON 30 lymph node 1.32 3.12 0.67 0.94 NA
S26 L. infantum MON 30 lymph node 1.04 1.03 1.01 1.02 NA
S27 L. infantum MON 30 lymph node 0.78 0.96 0.97 1.05 NA
S28 L. infantum MON 267 skin 0.93 7.13 2.48 0.95 NA
S29 L. donovani MON 18 skin 0.94 1.51 1.03 1.04 NA
S30 L. donovani MON 18 skin 22.2 62.8 1.83 0.63 1.1
an average ampliﬁcation level of 6.98. The MDR 1 gene
has been characterized in several Leishmania species. This
gene was initially found to be ampliﬁed in mutants selected
for vinblastine (V circles) [23] resistance and transfection
experiments showed that the product of this gene can induce
drug resistance by active extrusion of the drug. Experimental
studies showed that eﬄux could be inhibited by verapamil
[24]. This gene is highly homologous to the mammalian
MDR genes involved in resistance to anticancer drugs. The
ampliﬁcation level of MDR 1 we observed in Leishmania was
comparable to those reported for Plasmodium falciparum
in experimental studies [25]. Resistance of Plasmodium
falciparumtoquininehasbeenassociatedwithPfMDR1over
expression, was directly correlated to gene ampliﬁcation, and
confers cross resistance to other drugs [26]. The selection
of MDR amplicons could be explained by the intensive, or
perhaps exclusive, use of meglumine antimoniate for VL
treatment in Sudan and in veterinary practice in France.
So the frequency of MDR ampliﬁcation may reﬂects the
therapeutic pressure exerted on Leishmania. Katakura et al.
[27] obtained stable transfectants for L. amazonensis MDR
1 gene at a copy number over 500 under selective pressure
and, for PGP A, Guimond et al. [10] showed that a 2.2-
fold increase detected by means of microarray technology
was measured as a 12.7-fold increase by Southern blot. Our
resultsshowedthathighcopynumberofputativelyresistance
genes can also be observed in natural conditions; one strain
(S30) showed a very high copy number both for MDR 1 and
PGPA,respectively,63-and22-fold.PerformingduplexPCR
kepttheresultsclearofatechnicalerrorrelatedtodiﬀerences
in sample amounts introduced in the reaction tubes.
The PGP A was found ampliﬁed in ﬁve strains with
an average number of copy of 8.42, similar to the ratios
reported by Guimond after selection of metal resistant6 International Journal of Microbiology
Table 3: Primers and probes designed from the reference sequences of the studied genes.
Forward primer Reverse primer Probe Genbank access
PGP A GAGGGTGTGCAGATGCGGTA CATGAACGTCAGCAGCAGCG
FAM-CTTCCCACTCCC-
TGTCCGCCCGA-
TAMRA
X17154
MDR 1 GCGACCTGAACCTGACGATC GCCCGATCATCGACGACTTG
FAM-CGCACCCAG-
ACGACCCAGAGAACG-
TAMRA
L01572
GSH CTCCTTTGCGACACCGATGT GAGTCGTAGCGAGACTTGAGAAT
FAM-CGGCACCTC-
CTCCAAGCGGCG-
TAMRA
Y10049
DHFR GTACCTTGAGCTGATTGACC AGATGTGAATGGGGTCCTTGTCC
FAM-CTGCTGACG-
ACGAAGCGTGT-
TAMRA
AY122331
PTR 1 GCTGTCTGTTTGCACTATCA CTTGAAGAGGGTAACAGGTG
FAM-TTGGCAACG-
TTGCTCAGGTC-
TAMRA
AY547305
DNA POL TGTCGCTTGCAGACCAGATG GCATCGCAGGTGTGAGCAC
HEX-CCAGGCTCG-
AAGTTGTTGCTGCCC-
TAMRA
AF009141
ASC PEROX ATGATCTCTGAAAAGCTGGA AGGGATATCGAGACCTTTGT
HEX-GCTTCAAAC-
CGGAATGCCTG-
TAMRA
XM 001686044
Table 4: Reference values (means, standard deviations, thresholds)
from the sensitive reference strain and ampliﬁcation coeﬃcients of
the clinical primo-isolates displaying ampliﬁcation ratios above the
threshold values calculated from the reference strain.
PGP A MDR 1 GSH DHFR PTR1
Reference
strain
(calibrator,
10 replicates)
Mean
value
1.06 1.00 1.07 1.06 1.02
Standard
deviation
0.27 0.33 0.22 0.27 0.11
Threshold
value
1.87 1.99 1.73 1.87 1.35
Isolates
displaying
ampliﬁed
genes
Minimum
value
3.07 2.24 1.83 2.49 1.49
Maximum
value
22.2 62.8 2.48 16.05 2.7
Mean
value
8.42 6.98 2.41 10.6 1.85
Number
of isolates
53 0 3 53
strains [10]. PGP A belongs to the ATP binding cassette
transporters family, a subfamily of multidrug resistance
proteins (MRP). PGP A recognizes metal-thiol conjugates
and confers resistance to trivalent metals (AS III or Sb III
compounds) by accumulating the conjugates in intracellular
vesicles close to the ﬂagellar pocket [28]. The level of
resistance conferred by transfection of this gene is dependent
on the Leishmania species, suggesting that others factors
concur to resistance. In another study, Haimeur found that
the overproduction of PGP A was associated with GSH 1
gene ampliﬁcation [8]. Our ﬁndings showed that such a
concomitant ampliﬁcation of these genes also occurs in ﬁeld
strains in 3 out of 5 cases of PGP A ampliﬁcation.
Legare showed that an increase of trypanothione syn-
thesis concur to the detoxiﬁcation of the reduced antimony
compound [29]. GSH1 codes for the heavy subunit of
gamma-glutamylcysteine synthase [30], one of the enzymes
involved in trypanothione pathway and Grondin et al.
showed that GSH1 is overexpressed consecutively to gene
ampliﬁcation in metal resistant strains [31]. In the strains
under study, GSH ampliﬁcation seems to be a minor
event and further work has to be made for testing the
hypothesis of an overexpression without gene ampliﬁca-
tion.
Ampliﬁcation of the DHFR gene was only found in
ﬁve French L. infantum strains. DHFR-TS is a bifunctional
enzyme, involved in the main pathway of folates synthesis;
a duplication of its genomic region was ﬁrst described in
methotrexate resistant mutants [32]. One can hypothesise
that drug pressure was most important in the Mediterranean
area, due to the extended use of trimethoprime in veterinary
practice [33]. Guimond et al. found a 7.1 increase for DHFR
gene ampliﬁcation level in strains selected for resistance to
methotrexate [10]. We show here that some natural strains
presented with the same ampliﬁcation magnitude (average =
10.6). DHFR ampliﬁcation and mutations were also found
in malaria parasites under natural or experimental drug
pressure [34]. These mutations allowed to describe DHFR
alleles involved in pyrimethamine resistance and to perform
genetic studies about the spreading of resistance from Asia to
Africa [35].International Journal of Microbiology 7
Table 5: Distribution of the isolates displaying ampliﬁed genes according to the Leishmania species. ∗Ampliﬁcation observed only with
L. infantum.
Species PGP A MDR 1 GSH DHFR∗ PTR
N (%) of ampliﬁed genes 44 45 44 42 33
L. archibaldi (n = 6) 0 (0.0) 4 (66.7) 0 (0.0) 0 (0.0) 0 (0.0)
L. donovani (n = 17) 3 (20.0) 7 (43.8) 2 (13.3) 0 (0.0) 3 (21.4)
L. infantum (n = 23) 2 (8.7) 19 (82.6) 1 (4.4) 5 (21.7) 0 (0.0)
Total 5(11.4) 30 (66.7) 3(6.8) 5(11.9) 3 (9.1)
P = .36 P = .04 P = .44 P = .10 P = .11
Ampliﬁcation of the PTR1 gene appears uncommon in
our collection of natural strains. This ﬁnding is consistent
with the fact that antifolate chemotherapy is unsuccessful
in trypanosomatids and that ampliﬁcation of this gene
would be a physiological consequence of inhibition of DHFR
[36].
All these genes are known to be ampliﬁed as extrachro-
mosomal elements. The R region for DHFR, the H region for
PTR1 and PGP A were described after selection for resistance
tomethotrexateinL.tarentolae[37]andL.major [38].Inthe
present study, we do not observe such linkage, even in the F8
patient, showing the selection of ampliﬁed PGP A parasites.
MDR genes are coded by V circles or D circles, depending
on the drug used for their selection. LD1 region was the
ﬁrst extrachromosomal amplicon described in Leishmania
and was present in about 15% of the wild-type strains [39].
These elements participate to the plasticity of the Leishmania
genome.
Except for MDR 1, statistics showed that gene ampli-
ﬁcation was not associated with Leishmania species in a
signiﬁcant manner. This might be explained by relative low
numberofstrainsdisplaying genesampliﬁcationinthestudy
samples, leading to an insuﬃcient power to detect such
association.
Our ﬁndings illustrate the relevance of quantitative
molecular tools for studying gene ampliﬁcation potentially
involved in Leishmania drug resistance. The high frequency
and spreading of ampliﬁed genes among ﬁeld strains is
crucial for understanding drug resistance spreading and
therapeutic failure in Leishmania species. However, these
results, obtained from analysis of the promastigote stage,
need to be conﬁrmed on tissue amastigotes and clinical
signiﬁcance of such data warrants to be evaluated in further
studies that should compare gene ampliﬁcation to clinical
outcome of antimony therapy. In addition, the fact that
other mechanisms which could participate to antimony
resistance in natural conditions, such as variable gene
expression or altered proteins functionality, remains to be
documented.
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